- Projects & figures
- News & Events
- Managing your project
- About ERC
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths. European researchers developed novel ex vivo three-dimensional organoid cultures that replicate genetic events in CRC, as tools to test novel therapeutics.
Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Through her work with the fruit fly Drosophila santomea, Dr Virginie Orgogozo aims to answer one of the most challenging questions of modern evolutionary biology: how do observable characteristics change between species and yet remain stable in a given species?
Haematopoietic Stem Cells (HSCs) are blood cells located in the bone marrow. These cells are extensively used in research to develop treatments for many severe diseases, including HIV and multiple sclerosis, and their transplant is a key therapy for certain types of cancer like leukemia and multiple myeloma. However, the use of HSCs is seriously constrained by their limited availability since growing them in the lab does not produce very large quantities. There is therefore an urgent need for methods allowing scientists to multiply HSCs, without losing any of their properties.
Cancer is one of the most challenging medical issues we face. In the United Kingdom alone, there are 300,000 new cases every year – leading to almost two million surgical operations annually. Thanks to ERC funding, Dr Zoltán Takáts of Imperial College London has developed a ‘smart’ surgical knife that can ‘smell’ the tissues it is cutting through – with the potential to revolutionise cancer treatment, as well as food and drug analysis, and research into the human ‘microbiome’.